Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS.

Objective To analyze the changes induced by ocrelizumab in blood immune cells of patients with primary progressive MS (PPMS). Methods In this multicenter prospective study including 53 patients with PPMS who initiated ocrelizumab treatment, we determined effector, memory, and regulatory cells by flow cytometry at baseline and after 6 months of therapy. Wilcoxon matched paired tests were used to assess differences between baseline and 6 months9 results. p Values were corrected using the Bonferroni test. Results Ocrelizumab reduced the numbers of naive and memory B cells (p 10 pg/mL. Conclusions In PPMS, effector B-cell depletion changed T-cell response toward a low inflammatory profile, resulting in decreased sNfL levels.